Ir Variadi, ST, M.Eng, IPU, ASEAN.Eng kembali terpilih sebagai Ketua PII Kabupaten Aceh Besar untuk periode 2024-2027.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nahar menyampaikan bahwa anak-anak yang menjadi korban tindakan seksual rentan mengalami trauma berkepanjangan ...

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish ...

Alvotech announced that the European Medicines Agency (EMA) accepted a Marketing Authorization Application (MAA) for AVT03, a proposed biosimilar to Prolia® and Xgeva® (denosumab) and an MAA for AVT05 ...

Bandar Lampung (Lampost.co) -- Dinas Pemberdayaan Perempuan dan Perlindungan Anak (PPPA)  Lampung fokus untuk terus ...

Berolahraga sambil berwisata menjadi tren saat ini. Kegiatan yang kini menjadi gaya hidup masyarakat itu tidak bisa ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO ...

He noted that in the longer term, J&J 's sales of Simponi Aria (golimumab) continue to grow in rheumatoid arthritis. The company has noted that s J&J has also filed sirukumab in the US and EU ...

now an AbbVie company), Simponi for rheumatoid arthritis, Stelara for psoriasis and psoriatic arthritis, plus Invega Sustenna and Invega Trinza (schizophrenia). While Janssen is holding on to the ...

Simponi, J&J's second biologic to gain approval in 2009, is the fifth TNF-α inhibitor to reach what is now a lucrative but crowded market. It is going up against several mature product franchises ...